ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Significant Decrease in Short Interest

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 269,900 shares, a decline of 9.2% from the May 31st total of 297,400 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 433,000 shares, the short-interest ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

ASLN has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of ASLAN Pharmaceuticals in a research report on Friday, May 3rd. Piper Sandler reissued an “overweight” rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

Shares of ASLN stock traded down $0.02 during midday trading on Tuesday, reaching $0.28. 205,489 shares of the company were exchanged, compared to its average volume of 707,488. The company’s 50 day moving average price is $0.41 and its two-hundred day moving average price is $0.53. The company has a market cap of $4.59 million, a P/E ratio of -0.10 and a beta of 1.41. ASLAN Pharmaceuticals has a 12 month low of $0.27 and a 12 month high of $3.89.

ASLAN Pharmaceuticals’s stock is scheduled to reverse split before the market opens on Wednesday, July 3rd. The 1-8 reverse split was announced on Wednesday, July 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 3rd.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last released its earnings results on Thursday, May 9th. The company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.61). As a group, sell-side analysts predict that ASLAN Pharmaceuticals will post -2.55 earnings per share for the current year.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.